| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP)
TNXP Technical Analysis
4
| As on 9th Jun 2023 TNXP SHARE Price closed @ 1.83 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.79 & Strong Buy for SHORT-TERM with Stoploss of 0.27 we also expect STOCK to react on Following IMPORTANT LEVELS. |
TNXPSHARE Price
| Open | 1.85 | Change | Price | % |
| High | 1.89 | 1 Day | -0.06 | -3.17 |
| Low | 1.81 | 1 Week | 0.20 | 12.27 |
| Close | 1.83 | 1 Month | 1.39 | 315.91 |
| Volume | 140284 | 1 Year | 1.43 | 357.50 |
| 52 Week High 3.15 | 52 Week Low 0.09 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| TNXP Daily Charts |
TNXP Intraday Charts |
Whats New @ Bazaartrend |
TNXP Free Analysis |
|
|
TNXP Important Levels Intraday
| RESISTANCE | 1.98 |
| RESISTANCE | 1.93 |
| RESISTANCE | 1.90 |
| RESISTANCE | 1.87 |
| SUPPORT | 1.79 |
| SUPPORT | 1.76 |
| SUPPORT | 1.73 |
| SUPPORT | 1.68 |
TNXP Forecast April 2024
| 4th UP Forecast | 2.16 |
| 3rd UP Forecast | 2.05 |
| 2nd UP Forecast | 1.99 |
| 1st UP Forecast | 1.92 |
| 1st DOWN Forecast | 1.74 |
| 2nd DOWN Forecast | 1.67 |
| 3rd DOWN Forecast | 1.61 |
| 4th DOWN Forecast | 1.5 |
TNXP Weekly Forecast
| 4th UP Forecast | 1.95 |
| 3rd UP Forecast | 1.91 |
| 2nd UP Forecast | 1.89 |
| 1st UP Forecast | 1.86 |
| 1st DOWN Forecast | 1.80 |
| 2nd DOWN Forecast | 1.77 |
| 3rd DOWN Forecast | 1.75 |
| 4th DOWN Forecast | 1.71 |
TNXP Forecast2024
| 4th UP Forecast | 10.89 |
| 3rd UP Forecast | 7.98 |
| 2nd UP Forecast | 6.19 |
| 1st UP Forecast | 4.39 |
| 1st DOWN Forecast | -0.73 |
| 2nd DOWN Forecast | -2.53 |
| 3rd DOWN Forecast | -4.32 |
| 4th DOWN Forecast | -7.23 |
Tonix Pharmaceuticals Holding Corp ( NASDAQ USA Symbol : TNXP )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
TNXP Business Profile
Tonix Pharmaceuticals Holding Corp. discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company's lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer's disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment. Its preclinical pipeline includes TNX-1600 for PTSD, depression, and attention deficit hyperactivity disorder; TNX-1700 for gastric and pancreatic cancers; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500, a monoclonal antibody anti-CD40-L for organ transplant rejection autoimmunity; and TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome. It also develops TNX-2100, a COVID-19 skin test. It has collaboration agreements with Southern Research Institute, Columbia University, the University of Alberta, and Massachusetts General Hospital. The company was incorporated in 2007 and is headquartered in Chatham, New Jersey. Address: 26 Main Street, Chatham, NJ, United States, 07928
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service